Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva®) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.
Epistemonikos ID: 3852d88cb982eb44af3a8221f8f43c787319c07b
First added on: Mar 19, 2018